JRCT ID: jRCT2031230597
Registered date:26/01/2024
A phase III of KTZ-S 2% for Seborrhoeic dermatitis of the scalp
Basic Information
| Recruitment status | Not Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Seborrhoeic dermatitis of the scalp |
| Date of first enrollment | 17/02/2024 |
| Target sample size | 270 |
| Countries of recruitment | |
| Study type | Interventional |
| Intervention(s) | KTZ-S 2% once daily or once every 3 days for 4 weeks placebo once daily for 4 weeks |
Outcome(s)
| Primary Outcome | TSS change 4 weeks after the start of study treatment |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | >= 18age old |
|---|---|
| Age maximum | Not applicable |
| Gender | |
| Include criteria | Patients with seborrhoeic dermatitis of the scalp over 18 years old Malassezia fungi were detected of the lesions |
| Exclude criteria | Patients complicated with diseases considered inappropriate for participation in clinical trials such as serious cardiac / hepatic / renal / pulmonary / hematologic disease Patients with atopic dermatitis, psoriasis vulgaris, contact dermatitis, and inflammatory skin diseases other than seborrhoeic dermatitis of the scalp |
Related Information
| Primary Sponsor | Takahashi Hiromasa |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Shigeto Mashimo |
| Address | 1-2-13, Nihonbashi Ningyocho, Chuo-ku, Tokyo Tokyo Japan 103-0013 |
| Telephone | +81-3-5244-9343 |
| mashimo@serenpharma.com | |
| Affiliation | Seren Pharmaceuticals Inc. |
| Scientific contact | |
| Name | Hiromasa Takahashi |
| Address | 1-2-13, Nihonbashi Ningyocho, Chuo-ku, Tokyo Tokyo Japan 103-0013 |
| Telephone | +81-3-5244-9343 |
| takahashi@serenpharma.com | |
| Affiliation | Seren Pharmaceuticals Inc. |